Literature DB >> 25495113

Medical cost burdens among nonelderly adults with asthma.

Emily Carrier1, Peter Cunningham.   

Abstract

OBJECTIVES: We used the 2003-2009 Medical Expenditure Panel Survey to evaluate average annual total and out-of-pocket expenditures by nonelderly adults with asthma. STUDY
DESIGN: We divided patients diagnosed with asthma into 4 groups, based on whether or not they had had an asthma attack in the previous year (a crude marker for disease severity) and whether or not they reported using treatment for their asthma.
METHODS: For each group we calculated total and out-of-pocket average annual spending for hospital inpatient, hospital outpatient, emergency department, and physician office care, as well as for prescription drugs. These averages were adjusted to account for differences in respondents' overall health (presence of other co-morbidities, self-reported health status, and self-reported activity limitations), sociodemographic characteristics (age, sex, race/ethnicity, income), and insurance status.
RESULTS: We found that among the 4 groups, those who were receiving treatment but continued to experience asthma attacks had the highest total and out-of-pocket expenditures in all categories, consistent with their likely higher illness severity. However, patients who reported receiving treatment and did not experience attacks also reported relatively high adjusted total and out-of-pocket expenditures-most notably $536 per year out of pocket for prescription medications and $231 per year out of pocket for physician office visits. After adjustment, about the same proportion of patients in these 2 groups (13.5% who did not get treated and had attacks, and 13.8% who did get treated and avoided attacks) reported high financial burden.
CONCLUSIONS: Patients may experience financial challenges to appropriate self-management of asthma, even when they are able to avoid exacerbations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25495113

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  7 in total

1.  Effects of improvements in the CPS on the estimated prevalence of medical financial burdens.

Authors:  Steven C Hill; Keisha T Solomon; Johanna Catherine Maclean; Michael F Pesko
Journal:  Health Serv Res       Date:  2019-04-29       Impact factor: 3.402

Review 2.  Financial Toxicity: A Common but Rarely Discussed Treatment Side Effect.

Authors:  Cara McDermott
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 3.  Addressing the Regulatory and Scientific Challenges with Generic Orally Inhaled Drug Products.

Authors:  Bryan Newman; Kimberly Witzmann
Journal:  Pharmaceut Med       Date:  2020-04

4.  Association between hospitalizations for asthma exacerbation and weather conditions in Qingdao: an ecological study.

Authors:  Wei Han; Yi Su; Binglin Liu; Wenjing Zhu; Xinjuan Yu; Xiaohui Sun; Xuefei Qi; Xiaopei Lin; Syed A A Rizvi; Woo-Jung Song; Ji-Hyang Lee; Yasuo Shimizu; Ziguang Li; Qinghai Li
Journal:  Ann Transl Med       Date:  2022-04

5.  Who determines United States Healthcare out-of-pocket costs? Factor ranking and selection using ensemble learning.

Authors:  Chengcheng Zhang; Yujia Ding; Qidi Peng
Journal:  Health Inf Sci Syst       Date:  2021-06-07

6.  Costs Attributable to Overweight and Obesity in Working Asthma Patients in the United States.

Authors:  Chongwon Chang; Seung Mi Lee; Byoung Whui Choi; Jong Hwa Song; Hee Song; Sujin Jung; Yoon Kyeong Bai; Haedong Park; Seungwon Jeung; Dong Churl Suh
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

7.  Real-life effectiveness and safety of the inhalation suspension budesonide comparator vs the originator product for the treatment of patients with asthma: a historical cohort study using a US health claims database.

Authors:  David B Price; Eran Gefen; Gokul Gopalan; Cristiana Miglio; Rosie McDonald; Vicky Thomas; Simon Wan Yau Ming
Journal:  Pragmat Obs Res       Date:  2017-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.